These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 25201757)

  • 41. Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.
    Yan D; Jobe F; Hutchison RE; Mohi G
    Leukemia; 2015 Oct; 29(10):2050-61. PubMed ID: 26044284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.
    Mitsumori T; Nozaki Y; Kawashima I; Yamamoto T; Shobu Y; Nakajima K; Morishita S; Komatsu N; Kirito K
    Exp Hematol; 2014 Sep; 42(9):783-92.e1. PubMed ID: 24860972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Genetic and epigenetic abnormalities in myeloproliferative neoplasms].
    Kameda T; Shide K; Shimoda K
    Rinsho Ketsueki; 2015 Jun; 56(6):614-22. PubMed ID: 26256870
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myeloproliferative Neoplasms: The Long Wait for JAK2-Mutant Clone Expansion.
    Luque Paz D; Ashcroft P; Skoda RC
    Cell Stem Cell; 2021 Mar; 28(3):359-361. PubMed ID: 33667352
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Focus on the epigenome in the myeloproliferative neoplasms.
    Kim E; Abdel-Wahab O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circulating CD133+/–CD34– Have Increased c-
    Uslu Bıçak İ; Tokcan B; Yavuz AS; Tokdemir SS
    Turk J Haematol; 2023 Feb; 40(1):28-36. PubMed ID: 36458557
    [TBL] [Abstract][Full Text] [Related]  

  • 49. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2.
    Kagoya Y; Yoshimi A; Tsuruta-Kishino T; Arai S; Satoh T; Akira S; Kurokawa M
    Blood; 2014 Nov; 124(19):2996-3006. PubMed ID: 25217696
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.
    Chapeau EA; Mandon E; Gill J; Romanet V; Ebel N; Powajbo V; Andraos-Rey R; Qian Z; Kininis M; Zumstein-Mecker S; Ito M; Hynes NE; Tiedt R; Hofmann F; Eshkind L; Bockamp E; Kinzel B; Mueller M; Murakami M; Baffert F; Radimerski T
    PLoS One; 2019; 14(10):e0221635. PubMed ID: 31600213
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Recent advances in molecular pathogenesis of myeloproliferative neoplasms].
    Ikeda K
    Rinsho Ketsueki; 2016 Feb; 57(2):156-64. PubMed ID: 26935633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.
    Tefferi A; Gilliland DG
    Mayo Clin Proc; 2005 Jul; 80(7):947-58. PubMed ID: 16007902
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of Jak2 signaling reveals resistance of mouse embryonic hematopoietic stem cells to myeloproliferative disease mutation.
    Mascarenhas MI; Bacon WA; Kapeni C; Fitch SR; Kimber G; Cheng SW; Li J; Green AR; Ottersbach K
    Blood; 2016 May; 127(19):2298-309. PubMed ID: 26864339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of haemopoiesis: the use of cell markers and in vitro culture techniques in studies of clonal haemopathies in man.
    Adamson JW
    Clin Haematol; 1984 Jun; 13(2):489-502. PubMed ID: 6380854
    [TBL] [Abstract][Full Text] [Related]  

  • 55. JAK2V617F influences epigenomic changes in myeloproliferative neoplasms.
    Chen CC; Chiu CC; Lee KD; Hsu CC; Chen HC; Huang TH; Hsiao SH; Leu YW
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):470-476. PubMed ID: 29066347
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms.
    Beer PA; Ortmann CA; Stegelmann F; Guglielmelli P; Reilly JT; Larsen TS; Hasselbalch HC; Vannucchi AM; Möller P; Döhner K; Green AR
    Haematologica; 2010 Dec; 95(12):2153-6. PubMed ID: 20823136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.
    Oku S; Takenaka K; Kuriyama T; Shide K; Kumano T; Kikushige Y; Urata S; Yamauchi T; Iwamoto C; Shimoda HK; Miyamoto T; Nagafuji K; Kishimoto J; Shimoda K; Akashi K
    Br J Haematol; 2010 Aug; 150(3):334-44. PubMed ID: 20553273
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
    Hasselbalch HC
    Leuk Res; 2013 Feb; 37(2):214-20. PubMed ID: 23174192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
    Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
    Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A role for JAK2 mutations in myeloproliferative diseases.
    Morgan KJ; Gilliland DG
    Annu Rev Med; 2008; 59():213-22. PubMed ID: 17919086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.